Relating Observed Psychoactive Effects to the Plasma Concentrations of Delta-9-Tetrahydrocannabinol and Its Active Metabolite: An Effect-Compartment Modeling Approach

被引:10
作者
Awasthi, Rakesh [1 ]
An, Guohua [1 ]
Donovan, Maureen D. [1 ]
Ponto, Laura L. Boles [1 ,2 ]
机构
[1] Univ Iowa, Coll Pharm, Div Pharmaceut & Translat Therapeut, Iowa City, IA 52242 USA
[2] Univ Iowa, Positron Emiss Tomog Imaging Ctr, Dept Radiol, Iowa City, IA 52242 USA
关键词
pharmacokinetic/pharmacodynamic models; pharmacokinetics/pharmacodynamics; pharmacokinetics; metabolism; metabolite kinetics; clinical pharmacokinetics; population pharmacokinetics; EFFECT SITE; IN-VIVO; PHARMACOKINETICS; THC; DELTA(9)-TETRAHYDROCANNABINOL; MARIJUANA; TIME; PHARMACODYNAMICS; CANNABINOIDS; PHARMACOLOGY;
D O I
10.1016/j.xphs.2017.09.009
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The medical use of marijuana is increasing, yet little is known about the exposure-response relationship for its psychoactive effects. It is well known that the plasma concentrations of the principal psychoactive component of marijuana, Delta(9)-tetrahydrocannabinol (THC), do not directly correlate to the observed psychoactive effects. The purpose of this research was to use an effect-compartment modeling approach to predict and relate the concentrations of the psychoactive components (THC and its active metabolite) in the "hypothetical" effect-site compartment to the observed psychoactive effects. A "hypothetical" effect-compartment model was developed using literature data to characterize the observed delay in peak "highness" ratings compared with plasma concentrations of the psychoactive agents following intravenous administration of THC. A direct relationship was established between the reported psychoactive effects ("highness" or intoxication) and the predicted effect-site concentrations of THC. The differences between estimated equilibration half-lives for THC and THC-OH in the effect-compartment model indicated the differential equilibration of parent drug and the active metabolite between plasma and the effect-site. These models contribute to the understanding of the pharmacokinetic-pharmacodynamic relationships associated with marijuana use and are important steps in the prediction of pharmacodynamic effects related to the psychoactive components in marijuana. (c) 2018 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:745 / 755
页数:11
相关论文
共 31 条
[1]  
Adams IB, 1998, J PHARMACOL EXP THER, V284, P1209
[2]  
[Anonymous], HHS PUB
[3]   MARIJUANA EFFECT AND DELTA-9-TETRAHYDROCANNABINOL PLASMA-LEVEL [J].
CHIANG, CN ;
BARNETT, G .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 36 (02) :234-238
[4]   ACTIVITY OF DELTA-8-TETRAHYDROCANNABINOL AND DELTA-9-TETRAHYDROCANNABINOL AND RELATED COMPOUNDS IN MOUSE [J].
CHRISTENSEN, HD ;
FREUDENTHAL, RI ;
GIDLEY, JT ;
ROSENFELD, R ;
BOEGLI, G ;
TESTINO, L ;
BRINE, DR ;
PITT, CG ;
WALL, ME .
SCIENCE, 1971, 172 (3979) :165-+
[5]   RELATING BLOOD-CONCENTRATIONS OF TETRAHYDROCANNABINOL AND METABOLITES TO PHARMACOLOGICAL EFFECTS AND TIME OF MARIJUANA USAGE [J].
CONE, EJ ;
HUESTIS, MA .
THERAPEUTIC DRUG MONITORING, 1993, 15 (06) :527-532
[6]   Toward a Comprehensive Model of Δ9-Tetrahydrocannabinol Pharmacokinetics Using a Population Pharmacokinetics Approach [J].
Ginsburg, Brett C. .
CLINICAL PHARMACOKINETICS, 2015, 54 (02) :129-131
[7]   Pharmacokinetics and pharmacodynamics of cannabinoids [J].
Grotenhermen, F .
CLINICAL PHARMACOKINETICS, 2003, 42 (04) :327-360
[8]   Population Pharmacokinetic Model of THC Integrates Oral, Intravenous, and Pulmonary Dosing and Characterizes Short- and Long-term Pharmacokinetics [J].
Heuberger, Jules A. A. C. ;
Guan, Zheng ;
Oyetayo, Olubukayo-Opeyemi ;
Klumpers, Linda ;
Morrison, Paul D. ;
Beumer, Tim L. ;
van Gerven, Joop M. A. ;
Cohen, Adam F. ;
Freijer, Jan .
CLINICAL PHARMACOKINETICS, 2015, 54 (02) :209-219
[9]   KINETICS OF PHARMACOLOGIC RESPONSE [J].
HOLFORD, NHG ;
SHEINER, LB .
PHARMACOLOGY & THERAPEUTICS, 1982, 16 (02) :143-166
[10]   DO PLASMA-CONCENTRATIONS OF DELTA-9-TETRAHYDROCANNABINOL REFLECT THE DEGREE OF INTOXICATION [J].
HOLLISTER, LE ;
GILLESPIE, HK ;
OHLSSON, A ;
LINDGREN, JE ;
WAHLEN, A ;
AGURELL, S .
JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 21 (8-9) :S171-S177